Quick Answer
Inhibitor Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
Inhibitor Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $0.00 | $0.00 |
| Net Income | -$3.30M +1.2% |
-$3.34M -10.3% |
-$3.03M -125.0% |
$12.11M +4153.9% |
-$298.6K +71.8% |
-$1.06M +61.3% |
| Diluted EPS | -$0.02 +0.0% |
-$0.02 +0.0% |
-$0.02 -166.7% |
$0.03 | $0.00 | — |
| Total Assets | $2.51M -55.9% |
$5.69M -36.4% |
$8.95M -25.3% |
$11.98M +20271.4% |
$58.8K -55.4% |
$131.8K -85.4% |
| Cash and Equivalents | $2.38M -57.6% |
$5.61M -36.6% |
$8.84M -26.0% |
$11.95M +38923.1% |
$30.6K -59.2% |
$75.1K -90.7% |
| Stockholders Equity | -$1.29M -165.1% |
$1.99M -62.4% |
$5.28M -36.3% |
$8.30M +329.1% |
-$3.62M -7.8% |
-$3.36M -32.8% |
| R&D Expense | $1.70M -3.5% |
$1.76M +27.3% |
$1.38M +22356.4% |
$6.2K +25.4% |
$4.9K -97.4% |
$185.3K -84.7% |
| Operating Income | -$3.43M +6.3% |
-$3.66M -7.4% |
-$3.40M -417.5% |
-$657.9K -102.2% |
-$325.4K +69.3% |
-$1.06M +61.5% |
| Shares Outstanding | 172.57M +0.1% |
172.32M +0.2% |
172.02M +0.1% |
171.79M -54.4% |
376.86M +0.9% |
373.64M +0.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$712.2K | +2.6% | -7.9% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $3.14M | -51.4% | -19.8% |
| Cash and Equivalents | September 30, 2025 | $2.98M | -53.3% | -20.4% |
| Stockholders Equity | September 30, 2025 | $3.5K | -99.9% | -99.5% |
| R&D Expense | September 30, 2025 | $377.8K | +2.2% | +16.0% |
| Operating Income | September 30, 2025 | -$741.2K | +8.9% | -6.5% |
| Shares Outstanding | September 30, 2025 | 172.57M | +0.1% | +0.0% |
- Inhibitor Therapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
- Inhibitor Therapeutics, Inc. reported Net Income of -$3.30 million for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +1.2% in Net Income compared to the prior fiscal year.
- Inhibitor Therapeutics, Inc. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- Inhibitor Therapeutics, Inc. reported Total Assets of $2.51 million for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -55.9% in Total Assets compared to the prior fiscal year.
- Inhibitor Therapeutics, Inc. reported Cash and Equivalents of $2.38 million for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -57.6% in Cash and Equivalents compared to the prior fiscal year.
- Inhibitor Therapeutics, Inc. reported Stockholders Equity of -$1.29 million for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -165.1% in Stockholders Equity compared to the prior fiscal year.
- Inhibitor Therapeutics, Inc. reported R&D Expense of $1.70 million for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -3.5% in R&D Expense compared to the prior fiscal year.
- Inhibitor Therapeutics, Inc. reported Operating Income of -$3.43 million for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +6.3% in Operating Income compared to the prior fiscal year.
- Inhibitor Therapeutics, Inc. reported Shares Outstanding of 172.57 million shares for fiscal year 2025.
- Inhibitor Therapeutics, Inc. showed an increase of +0.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: